FILTER

Refine your search with the following facets to narrow down your results.

10 Current news of Ipsen

Ipsen to acquire a portfolio of select consumer healthcare products from Sanofi

13-Feb-2017 - Ipsen announced that it has entered into a definitive agreement to acquire five consumer healthcare products in certain European territories from Sanofi. The most significant product is Prontalgine® , an analgesic for the treatment of moderate to severe pain, which has grown at double digit rates ...

consumer healthcare Sanofi-aventis

Ipsen Enters Into Option Agreement to Acquire Canbex Therapeutics

27-Feb-2015 - Ipsen and Canbex Therapeutics Ltd announced that Canbex has granted Ipsen an option giving Ipsen the exclusive right to purchase 100% of Canbex shares upon completion of the Phase IIa study of Canbex’s lead candidate for the treatment of spasticity in people with multiple sclerosis (MS), known as ...

acquisitions

Ipsen announces positive results from phase III CLARINET study of Somatuline Autogel

15-Jul-2013 - Ipsen announced results from the primary endpoint of the CLARINET study, assessing the effect of Somatuline® Autogel® 120mg on tumor progression-free survival in patients with GEP-NETs. Treatment with Somatuline® Autogel® 120mg was found to be statistically significantly superior to placebo in ...

phase III studies

Oncodesign and LNGT: research collaboration for advancing drug discovery efforts with Ipsen in Parkinson's disease

04-Jan-2013 - Oncodesign and the Laboratory for Neurobiology and Gene Therapy (LNGT) at the department of neurosciences at the KU Leuven, an academic group exploring the roles of LRRK2 and a-synuclein in Parkinson’s disease headed by Professor Veerle Baekelandt, announced that they have entered into a research ...

drug discovery Parkinson's disease

Oncodesign and Ipsen enter into a research collaboration for the development of new therapeutic agents against the LRRK2 Parkinson's disease target

10-Jan-2012 - Oncodesign and Ipsen announced that the two companies have entered into a research collaboration to discover and develop LRRK2 kinase inhibitors as potential therapeutic agents against Parkinson's Disease and for potential additional uses in other therapeutic areas. Oncodesign and Ipsen will ...

Parkinson's disease research collaborations

Santhera and Ipsen Enter into Licensing Agreement for Fipame-zole for the Treatment of Dyskinesia in Parkinson's Disease

07-Sep-2010 - Santhera Pharmaceuticals and Ipsen announced a license agreement for the development and commercialization of fipamezole (antagonist of the adrenergic alpha-2 receptor) for territories outside of North America and Japan. This first-in-class compound is currently under investigation for the ...

dyskinesia levodopa induced dyskinesia license agreements +2

Ipsen and PHARNEXT conclude an exclusive research, development and marketing agreement

16-Jun-2009 - Ipsen and Pharnext SAS, a biopharmaceutical company specializing in the development of innovative treatments, today announced they have entered into an exclusive research, development and marketing agreement regarding innovative drug candidates intended for the treatment of Charcot Marie-Tooth ...

clinical trials USA

bioMérieux and Ipsen Sign Theragnostics Agreement to Develop Companion Test for New Breast Cancer Treatment

19-Sep-2007 - bioMérieux and Ipsen announced that they have signed an agreement by which bioMérieux will develop a companion test for a new breast cancer drug undergoing clinical evaluation by Ipsen. The development will be co-funded by bioMérieux and Ipsen. Ipsen is developing a novel breast cancer therapy, ...

breast cancer diagnostic tests Enzyme +2

bioMérieux will be awarded up to EUR54.5 million by France's Agence de l'Innovation Industrielle for molecular biology research

28-Nov-2006 - bioMérieux announced that it will be awarded up to EUR54.5 million over the next ten years by France's Agence de l'Innovation Industrielle to help fund the "Advanced Diagnostics and New therapeutic Approaches" (ADNA) program, led by Mérieux Alliance. Of this amount, EUR25.6 million will be in the ...

biomarkers diagnostic tests diagnostics +4

Genentech And Ipsen Agree To Develop Sustained-Release Formulations Of Recombinant Human Growth Hormone

23-Mar-2005 - Genentech, Inc. and Ipsen announced the recent execution of a collaborative research and development (R&D) agreement to develop sustained-release formulations of Genentech's recombinant human growth hormone [somatropin (rDNA origin)]. This R&D collaboration is in addition to and supplements a ...

food Genentech